Novartis announced that Cosentyx (secukinumab) has received FDA approval for treatment of children and adolescents with
Tweet Content
Novartis announced that Cosentyx (secukinumab) has received FDA approval for treatment of children and adolescents with moderate to severe plaque psoriasis #EULAR2021 https://t.co/JlkmjLwqQ8
Links
Show on Archive Page
On
Display in Search Results
On
PDQ
Off